Literature DB >> 23975301

Geographic and temporal trends in the management of occult primary breast cancer: a systematic review and meta-analysis.

Oluwadamilola M Fayanju1, Carolyn R T Stoll, Susan Fowler, Graham A Colditz, Donna B Jeffe, Julie A Margenthaler.   

Abstract

BACKGROUND: Management of occult primary breast cancer (OPBC), including the role of magnetic resonance imaging (MRI), is controversial. We conducted a pooled analysis of OPBC patients and a meta-analysis of MRI accuracy in OPBC in order to elucidate current practices.
METHODS: A literature search yielded 201 studies. Patient-level data for clinically/mammographically OPBC from studies published after 1993 and from our institution were pooled; logistic regression examined associations between patient/study data and outcomes, including treatments and recurrence. We report adjusted odds ratios (OR) and 95 % confidence intervals (95 % CI) significant at 2-tailed p < 0.05. Meta-analysis included data for patients who received MRIs for workup of clinically/mammographically OPBC. We report pooled sensitivity and specificity with 95 % CIs.
RESULTS: The pooled analysis included 92 patients (15 studies [n = 85] plus our institution [n = 7]). Patients from Asia were more likely to receive breast surgery (OR = 5.98, 95 % CI = 2.02-17.65) but not chemotherapy (OR = 0.32, 95 % CI = 0.13-0.82); patients from the United States were more likely to receive chemotherapy (OR = 13.08, 95 % CI = 2.64-64.78). Patients from studies published after 2003 were more likely to receive radiotherapy (OR = 3.86, 95 % CI = 1.41-10.55). Chemotherapy recipients were more likely to have distant recurrence (OR = 9.77, 95 % CI = 1.10-87.21). More patients with positive MRIs received chemotherapy than patients with negative MRIs (10 of 12 [83.3 %] vs 5 of 13 [38.5 %]; p = 0.0414). In the MRI-accuracy meta-analysis (10 studies, n = 262), pooled sensitivity and specificity were 96 % (95 % CI = 91-98 %) and 63 % (95 % CI = 42-81 %), respectively.
CONCLUSIONS: OPBC management varied geographically and over time. We recommend establishing an international OPBC patient registry to facilitate longitudinal study and develop global treatment standards.

Entities:  

Mesh:

Year:  2013        PMID: 23975301      PMCID: PMC3922044          DOI: 10.1245/s10434-013-3157-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  59 in total

1.  Impact of breast MR in non-screening Australian clinical practice: audit data from a single-reader single-centre site.

Authors:  Esber N El-Barhoun; Alexander G Pitman
Journal:  J Med Imaging Radiat Oncol       Date:  2011-10       Impact factor: 1.735

2.  Bilateral axillary metastases of occult breast carcinoma: report of a case with a review of the literature.

Authors:  M Steunebrink; J M Schnater; R K Storm; G van Ingen; P A Vegt; P W Plaisier
Journal:  Breast       Date:  2005-04       Impact factor: 4.380

3.  MRI of the breast in patients with metastatic disease of unknown primary.

Authors:  C Schorn; U Fischer; S Luftner-Nagel; J P Westerhof; E Grabbe
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

4.  Role of breast magnetic resonance imaging in determining breast as a source of unknown metastatic lymphadenopathy.

Authors:  R S Henry-Tillman; S E Harms; K C Westbrook; S Korourian; V S Klimberg
Journal:  Am J Surg       Date:  1999-12       Impact factor: 2.565

Review 5.  Imaging breast cancer.

Authors:  Lia Bartella; Clare S Smith; D David Dershaw; Laura Liberman
Journal:  Radiol Clin North Am       Date:  2007-01       Impact factor: 2.303

Review 6.  MRI in the detection and management of breast cancer.

Authors:  Anwar R Padhani; Mei-Lin W Ah-See; Andreas Makris
Journal:  Expert Rev Anticancer Ther       Date:  2005-04       Impact factor: 4.512

7.  Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients.

Authors:  P P Rosen; M Kimmel
Journal:  Hum Pathol       Date:  1990-05       Impact factor: 3.466

8.  Axillary lymph node metastasis from an occult breast cancer.

Authors:  J Patel; T Nemoto; D Rosner; T L Dao; J W Pickren
Journal:  Cancer       Date:  1981-06-15       Impact factor: 6.860

9.  Occult breast cancer presenting with axillary metastases. Updated management.

Authors:  P L Baron; M P Moore; D W Kinne; F C Candela; M P Osborne; J A Petrek
Journal:  Arch Surg       Date:  1990-02

10.  Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis.

Authors:  Ramya Varadarajan; Stephen B Edge; Jihnhee Yu; Nancy Watroba; Bagi R Janarthanan
Journal:  Oncology       Date:  2007-08-09       Impact factor: 2.935

View more
  4 in total

1.  Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+).

Authors:  Damian P McCartan; Emily C Zabor; Monica Morrow; Kimberly J Van Zee; Mahmoud B El-Tamer
Journal:  Ann Surg Oncol       Date:  2017-07-12       Impact factor: 5.344

2.  Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.

Authors:  Allicia C Girvan; Gebra C Carter; Li Li; Anna Kaltenboeck; Jasmina Ivanova; Maria Koh; Jessi Stevens; Eleanor Hayes-Larson; Michael M Lahn
Journal:  Drugs Context       Date:  2015-03-10

3.  Evaluation of the Benefit of Radiotherapy in Patients with Occult Breast Cancer: A Population-Based Analysis of the SEER Database.

Authors:  Byoung Hyuck Kim; Jeanny Kwon; Kyubo Kim
Journal:  Cancer Res Treat       Date:  2017-06-01       Impact factor: 4.679

4.  Comparable Survival between Additional Radiotherapy and Local Surgery in Occult Breast Cancer after Axillary Lymph Node Dissection: A Population-based Analysis.

Authors:  San-Gang Wu; Wen-Wen Zhang; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Yong-Xiong Chen; Zhen-Yu He
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.